<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369862</url>
  </required_header>
  <id_info>
    <org_study_id>GHB-CS08</org_study_id>
    <nct_id>NCT01369862</nct_id>
  </id_info>
  <brief_title>Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Phase I/II Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVIR Green Hills Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVIR Green Hills Biotechnology AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase I/II trial is to evaluate safety and tolerability of a single dose&#xD;
      of GHB16L2 administered by liquid nasal spray for vaccination against seasonal influenza&#xD;
      virus infection. It is also performed to assess immunogenicity and pharmacokinetics&#xD;
      (shedding).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GHB16L2 intends to provide a novel vaccination for influenza virus infection. 80 healthy&#xD;
      volunteers will be included at a ratio of 1:1 for GHB16L2 or placebo. GHB16L2 will be&#xD;
      administered once on day 1. Follow-up visits will be performed on days 2, 8 and 29.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>From baseline to 30 days after end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rates at day 29</measure>
    <time_frame>At day 29 (end of study)</time_frame>
    <description>Seroconversion rates for HAI, MNA, IgA and IgG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the presence of GHB16L2 in mucosal samples (viral recovery/shedding)</measure>
    <time_frame>1 week post immunisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response factor at day 29</measure>
    <time_frame>At day 29 (end of study)</time_frame>
    <description>Immune response factors for HAI, MNA, IgA and IgG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>SPGNH buffer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SPGNH buffer administration by liquid nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GHB16L2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level ~7.0 log10 fTCID50/strain/person</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GHB16L2</intervention_name>
    <description>A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants</description>
    <arm_group_label>GHB16L2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SPGNH buffer</description>
    <arm_group_label>SPGNH buffer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female volunteers, 18-60 years&#xD;
&#xD;
          -  Seronegative for one or two of the applied vaccine strains&#xD;
&#xD;
          -  Low antibody titres for H1N1v&#xD;
&#xD;
          -  Written informed consent to participate in this study&#xD;
&#xD;
          -  For female volunteers of childbearing potential, provision of a history and current&#xD;
             use of reliable contraceptive practices&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute febrile illness (&gt;37.3°C)&#xD;
&#xD;
          -  Signs of acute or chronic upper or lower tract respiratory illnesses&#xD;
&#xD;
          -  History of severe atopy&#xD;
&#xD;
          -  Seasonal influenza vaccination in 2008/2009 and/or later seasons and/or pandemic&#xD;
             influenza vaccination at any time&#xD;
&#xD;
          -  Fever ≥38.0°C in the time period between the pre-screening visit and day 1&#xD;
&#xD;
          -  Known increased tendency of nose bleeding&#xD;
&#xD;
          -  Volunteers with clinically relevant abnormal paranasal anatomy&#xD;
&#xD;
          -  Volunteers with clinically relevant abnormal laboratory values&#xD;
&#xD;
          -  In female volunteers of childbearing potential, a positive urine pregnancy test&#xD;
&#xD;
          -  Simultaneous treatment with immunosuppressive drugs incl. Corticosteroids (≥2 weeks)&#xD;
             within 4 weeks prior to study medication application&#xD;
&#xD;
          -  Clinically relevant history of renal, hepatic, GI, cardiovascular, haematological,&#xD;
             skin, endocrine, neurological or immunological diseases&#xD;
&#xD;
          -  History of leukaemia or cancer&#xD;
&#xD;
          -  HIV or Hepatitis B or C seropositivity&#xD;
&#xD;
          -  Volunteers who underwent rhino or sinus surgery, or surgery of another traumatic&#xD;
             injury of the nose within 30 days prior to application of study medication&#xD;
&#xD;
          -  Volunteers who have received antiviral drugs, treatment with immunoglobulins or blood&#xD;
             transfusions, or an investigational drug within 4 weeks prior to study medication&#xD;
             application&#xD;
&#xD;
          -  Volunteers who have received anti-inflammatory drugs 2 days prior to study medication&#xD;
             application&#xD;
&#xD;
          -  Volunteers who are not likely to cope with the requirements of the study or with a&#xD;
             significant physical or mental condition that may interfere with the completion of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wolzt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna, Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <name_title>Thomas Muster PhD, CEO/CSO</name_title>
    <organization>AVIR Green Hills Biotechnology AG</organization>
  </responsible_party>
  <keyword>live attenuated flu vaccines</keyword>
  <keyword>influenza A (H1N1)</keyword>
  <keyword>intranasal application</keyword>
  <keyword>replication-deficient influenza virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

